Five-year data from the ABSORB III trial suggest that excess risk with bioresorbable vascular scaffolds ends at three years. A lead investigator explains why these findings mean the technology still holds potential.
An FDA advisory panel just recommended approval of what may be the nation’s first bioresorbable stent. Here’s why an ABSORB III trial investigator wasn’t surprised that interim results didn’t find it superior to a standard DES.
New developments promise further progress against restenosis and thrombosis after percutaneous vascular interventions. Cleveland Clinic interventionalists share perspectives on three leading developments.